Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03340454
Other study ID # 17-01446
Secondary ID 2U54MD000538
Status Completed
Phase N/A
First received
Last updated
Start date August 15, 2018
Est. completion date June 15, 2023

Study information

Verified date March 2024
Source NYU Langone Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the efficacy, adoption, and impact of an integrated intervention to improve adherence to recommended stomach cancer prevention guidelines (H. pylori test-and-treat) for at-risk Chinese Americans in NYC. The integrated multifaceted theory-based intervention involves: 1) a health systems-level intervention using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies; and 2) a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability. Using a 2-arm randomized controlled trial (RCT) design, > 144 Chinese American patients across NYC safety net hospital endoscopy clinics and primary health centers will participate.


Recruitment information / eligibility

Status Completed
Enrollment 135
Est. completion date June 15, 2023
Est. primary completion date June 15, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - self identifies as Chinese American - is an outpatient aged 21 years and older (adult) - plans to continue to live in the region during the next 12 months; - is willing to be randomized to either treatment or control groups - has a confirmed diagnosis of H. pylori infection by at least one of the following methods: C-urea breath test, histology, rapid urease test or bacterial culture, fecal stool antigen test or other clinically approved H. pylori infection diagnostic test. Exclusion Criteria: - advanced chronic disease that would not allow the patient to complete follow-up or attend visits; - allergy to any of the study drugs; - pregnancy or currently breastfeeding - taking antibiotics or bismuth salts within 2 weeks before the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Test-and-treat EHR-CHW intervention
a health systems-level intervention using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies
Usual care of EHR-only intervention
a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability.

Locations

Country Name City State
United States New York University School of Medicine New York New York

Sponsors (2)

Lead Sponsor Collaborator
NYU Langone Health National Institute on Minority Health and Health Disparities (NIMHD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Eradication of H. pylori Measured using breath ammonia measurement, fecal stool antigen test or other clinically approved H. pylori infection diagnostic test. Data extracted from patient EHR. Up to Month 3-Post Treatment
Secondary Ottawa Decision Self-Efficacy Scale Score at Baseline 11- item assessment of participant's confidence in making an informed choice. For each item, confidence is rated on a 5-point Likert scale from 0 (not at all confident) to 4 (very confident). The total score is the sum of responses and ranges from 0 to 44; higher scores indicate greater decision self-efficacy. Baseline
Secondary Ottawa Decision Self-Efficacy Scale Score at Month 2 11- item assessment of participant's confidence in making an informed choice. For each item, confidence is rated on a 5-point Likert scale from 0 (not at all confident) to 4 (very confident). The total score is the sum of responses and ranges from 0 to 44; higher scores indicate greater decision self-efficacy. Month 2
Secondary Ottawa Decision Self-Efficacy Scale Score at Month 6 11- item assessment of participant's confidence in making an informed choice. For each item, confidence is rated on a 5-point Likert scale from 0 (not at all confident) to 4 (very confident). The total score is the sum of responses and ranges from 0 to 44; higher scores indicate greater decision self-efficacy. Month 6
Secondary Number of Patients determined to be Adherent per Medication Adherence Report Scale (MARS-5) Score at Baseline "The MARS-5 is a 5-item self-assessment of medication adherence. The first item assesses unintentional non-adherence, while the four other items assess intentional non-adherence. Participants indicated how often each statement applied to them in the past month on a 5-point Likert scale (1=always, 2=often, 3=sometimes, 4=rarely, 5=never), resulting in a total score ranging from 5 to 25. Non-adherence is defined as reporting any non-adherence on the MARS (total score <25). Adherence is defined as a score of 25." Baseline
Secondary Number of Patients determined to be Adherent per MARS-5 Score at Month 2 "The MARS-5 is a 5-item self-assessment of medication adherence. The first item assesses unintentional non-adherence, while the four other items assess intentional non-adherence. Participants indicated how often each statement applied to them in the past month on a 5-point Likert scale (1=always, 2=often, 3=sometimes, 4=rarely, 5=never), resulting in a total score ranging from 5 to 25. Non-adherence is defined as reporting any non-adherence on the MARS (total score <25). Adherence is defined as a score of 25." Month 2
Secondary Number of Patients determined to be Adherent per MARS-5 Score at Month 6 "The MARS-5 is a 5-item self-assessment of medication adherence. The first item assesses unintentional non-adherence, while the four other items assess intentional non-adherence. Participants indicated how often each statement applied to them in the past month on a 5-point Likert scale (1=always, 2=often, 3=sometimes, 4=rarely, 5=never), resulting in a total score ranging from 5 to 25. Non-adherence is defined as reporting any non-adherence on the MARS (total score <25). Adherence is defined as a score of 25." Month 6
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06045494 - The Efficacy of Treatment for Helicobacter Pylori Infection in Preschooler by Yoghurt With LG21 N/A
Not yet recruiting NCT01449500 - Supplementation With L. Reuteri in H. Pylori Infected Adults N/A
Completed NCT01234389 - Immediate Detection of Helicobacter Infection With a New Electrochemical System. N/A
Not yet recruiting NCT05387005 - Screening Strategy for Gastric Cancer Prevention N/A
Not yet recruiting NCT02761005 - Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori Phase 2
Recruiting NCT03142620 - Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study Phase 3
Withdrawn NCT02090738 - A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide Phase 2
Recruiting NCT01335334 - H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study Phase 4
Recruiting NCT05544396 - Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis. N/A
Recruiting NCT04713670 - Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection Phase 4
Recruiting NCT06045832 - Oral Helicobacter Pylori Eradication N/A
Completed NCT05453994 - Bismuth for PCAB-based H. Pylori Eradication
Recruiting NCT02328131 - European Registry on the Management of Helicobacter Pylori Infection
Completed NCT00197457 - Pepsinogens as the Early Marker of H. Pylori Eradication Phase 2
Not yet recruiting NCT06412640 - Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori Phase 4
Completed NCT04036838 - ARJ C13 Urea Breath Test System Phase 2
Completed NCT06050824 - A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection Phase 4
Completed NCT02767479 - Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori Phase 3
Completed NCT01505127 - Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori Phase 3
Recruiting NCT05176821 - Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection N/A